ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2806

Characteristic Phenotype of Peripheral Blood Lymphocytes in Patients with IgG4-Related Disease, Comparing to Primary Sjögren Syndrome and Healthy Controls

Shintaro Hirata, Shingo Nakayamada, Satoshi Kubo, Maiko Yoshikawa, Naoki Yunoue, Kazuhisa Nakano, Kunihiro Yamaoka, Kazuyoshi Saito and Yoshiya Tanaka, The First Department of Internal Medicine, University of Occupational and Environmental Health, Japan, Kitakyushu, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: B cells, IgG4 Related Disease, Sjogren's syndrome, T cells and flow cytometry

  • Tweet
  • Email
  • Print
Session Information

Title: Miscellaneous Rheumatic and Inflammatory Diseases/Innate Immunity and Rheumatic Disease: Assessing Outcomes of Infections in Rheumatic Disease

Session Type: Abstract Submissions (ACR)

Background/Purpose : IgG4-related disease (IgG4-RD) is a systemic disease that is characterized by the infiltration of IgG4-positive plasma cells and T cells into various organs. However, the characteristic and pathological role of immune cell subsets remains unclear. We have characterized peripheral blood immune cell subsets in patients with IgG4-RD by comparing with patients with primary Sjögren syndrome (pSS) and healthy controls (HC).

Methods : PBMCs were obtained from 8 IgG4-RD and 4 pSS patients as well as from 8 HC. The phenotype of immune cells was analyzed by 8-color staining flow cytometry. T helper cells were categorized as naive, central memory, effector memory and effector T cells by expression of CCR7 and CD45RA. B cells were categorized as naive, IgM memory, switched memory, effector B cell and plasmablast (PB) by expression of IgD, CD27 and CD38. DCs were categorized as myeloid and plasmacytoid DC by expression of CD11c and CD123. The proportion of immune cell subsets was assessed for correlations with serological parameters, including serum IgG, IgG4, and CRP.

Results : Baseline characteristics of patients with IgG4-RD (mean ± SD) were; age 56 ± 20 year, symptom duration 16.3 ± 19.2 months, serum IgG4 628 ± 549 mg/dl, CRP 1.3 ± 2.6 mg/dl, respectively. There was no difference in the proportion of T helper cells (Th1, Th2, Th17, Treg), B cells or DC subsets between IgG4-RD, and pSS, HC,whereas CD3+CD4+CXCR5+CD45RA– Tfh cells were significantly higher in IgG4-RD than HC (p=0.033). In contrast, the proportion of CD3+CD4+CCR7–CD45RA+ effector T cells and CD19+CD27+CD20–CD38+ plasmablasts significantly increased in IgG4-RD compared to pSS and HC (p values: 0.008 and 0.013, respectively). Importantly, the proportion of CD3+CD4+CCR7–CD45RA– effector memory T helper cells was strongly correlated with the ratio of serum IgG4/IgG ratio (rho=0.90, p=0.002), whereas it was not with that of plasmablasts (rho=0.17, p=0.67).

Conclusion : These results revealed that the higher proportion of effector T cells including Tfh cells and the increase of plasmablasts possibly induced by Tfh are characteristically observed in IgG4-RD, but not in pSS. Moreover, serum IgG4/IgG ratio was strongly correlated with ratio of effector memory T cells, but not plasmablasts. Taken together, IgG4 overproduction may be conducted by matured effector phase helper T cells, suggesting a pivotal role of effector phase T cells in pathogenesis of IgG4RD, especially in IgG4 specific production. Further studies are required to elucidate the detailed role of effector phase T cells in the pathogenesis of IgG4-RD.


Disclosure:

S. Hirata,
None;

S. Nakayamada,
None;

S. Kubo,
None;

M. Yoshikawa,
None;

N. Yunoue,
None;

K. Nakano,
None;

K. Yamaoka,
None;

K. Saito,
None;

Y. Tanaka,

BMS, MSD, Chugai, Mitsubishi-Tanabe, Astellas, Abbvie, Daiichi-Sankyo,

2,

UCB Pharma, Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei,

5,

UCB, Mitsubishi-Tanabe, Abbott, Abbvie, Eisai, Chugai, Janssen, Pfizer, Takeda, Astellas, Daiichi-Sankyo, GSK, AstraZeneca, Eli Lilly, Quintiles, MSD, Asahi Kasei,

8.

  • Tweet
  • Email
  • Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/characteristic-phenotype-of-peripheral-blood-lymphocytes-in-patients-with-igg4-related-disease-comparing-to-primary-sjogren-syndrome-and-healthy-controls/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology